Share
- Release Date: 15/10/12 11:00
- Summary: GENERAL: BLT: New Research BLIS K12 probiotic in dogs
- Price Sensitive: No
- Download Document 2.35KB
BLT
15/10/2012 09:00
GENERAL
REL: 0900 HRS BLIS Technologies Limited
GENERAL: BLT: New Research BLIS K12 probiotic in dogs
New research looks at the benefit of BLIS K12(TM) probiotic in dogs
BLIS Technologies Ltd (NZX:BLT) announces the successful completion of the
first phase in a research programme, which focuses on preventing bad breath
in dogs. According to the programme leader at BLIS Technologies, Dr John
Hale the BLIS K12(TM) probiotic, which is already known for its ability to
inhibit bacteria responsible for the severe bad breath in humans, has been
given to dogs to determine if bad breath can be reduced or eliminated in
companion animals.
"The trial was a pilot study to determine the viability of the BLIS K12(TM)
probiotic in a dog's mouth, using either a liquid and solid dose form" Hale
said. "The results from this small pilot trial were encouraging enough to
commence a longer, extended dosing trial in dogs, which started in Dunedin
last week"
The study was made possible through collaboration between BLIS Technologies
and the Otago Polytechnic School of Veterinary Nursing, where many of the
staff have volunteered their own dogs for the trial. BLIS Technologies has
already undertaken bench-top studies in their own laboratory and found that
their BLIS K12(TM) probiotic was able to inhibit around 50% of the various
bacteria of a dog's mouth and this is a big part of the reason why the
Company has undertaken these trials in dogs.
Bacterial infections of the teeth and gums in dogs and cats are increasing
problem, according to the veterinary industry and while BLIS Technologies is
currently just focused on bacterial bad breath in dogs, it is hoped that the
Company could eventually expand its research into the animal periodontal
area.
"This research represents further evidence that the BLIS K12(TM) probiotic is
a highly versatile organism and plays an important role in the Company's
commercial strategy " said Dr Barry Richardson, Chief Executive of BLIS
Technologies. "We believe that this early data points to a beneficial effect
in dogs and we would expect further studies to confirm this effect before
commercialization in the animal market."
YOUR CONTACT:
Dr Barry Richardson
BLIS Technologies Ltd
PO Box 56 ?87 St David Street ?Dunedin?New Zealand
Phone +64 (3) 479 5337
www.blis.co.nz
End CA:00228432 For:BLT Type:GENERAL Time:2012-10-15 09:00:09
